Cyclo Therapeutics Equity Warrants Exp 14th Nov 2025 *W EXP 12/11/2025
Change company Symbol lookup
Select an option...
CYTHW Cyclo Therapeutics Equity Warrants Exp 14th Nov 2025 *W EXP 12/11/2025
FR First Industrial Realty Trust Inc
PNI PIMCO New York Municipal Income Fund II
NIB iPath? Bloomberg Cocoa Subindex Total Return(SM) ETN
DG Dollar General Corp
SPCO Stephan Co
KEX Kirby Corp
GM General Motors Co
F Ford Motor Co
MSFT Microsoft Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Cyclo Therapeutics, Inc. is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. It is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The Company's product lines include Trappsol and Aquaplex. It sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Closing Price
$0.76
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.78
Day's Low
0.5088
Volume
(Above Average)
Volume:
1,592

10-day average volume:
1,592
1,592

GENERAL MILLS INC. INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Continues Its Investigation of General Mills Inc.'s Directors and Officers for Breach of Fiduciary Duties - GIS

5:42 pm ET June 23, 2022 (BusinessWire) Print

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, reminds investors it is investigating whether certain directors and officers of General Mills, Inc. ("General Mills") (NYSE: GIS) breached their fiduciary duties to General Mills and its shareholders. If you are a General Mills shareholder, you are encouraged to contact attorney Joe Pettigrew with Scott+Scott for additional information at (844) 818-6982 or jpettigrew@scott-scott.com.

Scott+Scott is investigating whether members of General Mills's board of directors or senior management failed to manage General Mills in an acceptable manner, in breach of their fiduciary duties to General Mills, and whether General Mills and its shareholders have suffered damages as a result.

On April 18, 2022, the New York Times reported that the U.S. Food and Drug Administration ("FDA") was investigating reports that thousands of people had become ill after eating Lucky Charms cereal. According to the article, the FDA stated that its own reporting system had received more than 100 submissions related to Lucky Charms in 2022 thus far.

What You Can Do

If you are a General Mills shareholder, you may have legal claims against General Mills's directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

Attorney Advertising

View source version on businesswire.com: https://www.businesswire.com/news/home/20220623006001/en/

SOURCE: Scott+Scott Attorneys at Law LLP

Joe Pettigrew 
Scott+Scott Attorneys at Law LLP 
600 W. Broadway, Suite 3300, San Diego, CA 92101 
(844) 818-6982 
jpettigrew@scott-scott.com
comtex tracking

COMTEX_409138289/1006/2022-06-23T17:42:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.